Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months

Table 1

Demographic and clinical characteristics of patients. Data presented as mean [SD] for continuous variables and proportions (%) for categorical variables unless otherwise stated.

Characteristics	Bolus-infusion delays
	0–8 minutes (𝑛=121)	>8 minutes (𝑛=108)
Male sex	50	56
Mean age (years)	73 [11]	72[12]
Mean weight (kg)	72 [14]	76[16]
Mean systolic blood pressure (mmHg)	144 [22]	142[22]
Mean diastolic blood pressure (mmHg)	78 [15]	76[15]
Mean admission blood glucose (mmol/L)	7[2]	7[3]
Hypertension	71	59
Diabetes mellitus	13	12
Atrial fibrillation	37	45
Congestive cardiac failure	8	4
Hyperlipidaemia	45	45
TIA/amaurosis fugax	10	6
Previous stroke	14	12
Peripheral vascular disease	6	5
Myocardial infarction or ischaemic heart disease	19	30
Current smoker	15	18
Ex-smoker	26	22
Antiplatelet use	53	60
Pre-stroke mRS, median (IQR)	1 (0–2)	1 (0–2)
Mean onset to treatment time (OTT) in minutes; proportions within groups
0–90	79[11]; 11%	74[16]; 18%
91–180	132[25]; 63%	132 [26]; 64%
181–270	212[19]; 26%	209[22]; 18%
0–270	147[47]	136[47]
Oxfordshire Community Stroke Project
Total anterior circulatory stroke	41	56
Partial anterior circulatory stroke	45	35
Lacunar stroke	12	6
Posterior circulatory stroke	2	4
Pre-thrombolysis neurological severity per NIHSS score
Median (IQR)*	10[7–17]	14.5[9–21]
Proportions within NIHSS categories (%)**
0–9	49	30
10–19	35	37
>19	16	33

NIHSS—National Institutes of Health Stroke Scale; TIA—Transient Ischaemic Attack; mRS—modified Rankin Score. No significant differences between infusion delays of 0–8 and >8 minutes except for *(Mann Whitney U test, 𝑃=0.016) and **(Pearson’s χ2 test = 13.1, 𝑃=0.001).